Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Arcus Biosciences (RCUS) Revenue (2017 - 2025)

Arcus Biosciences has reported Revenue over the past 9 years, most recently at $33.0 million for Q4 2025.

  • Quarterly results put Revenue at $33.0 million for Q4 2025, up 26.92% from a year ago — trailing twelve months through Dec 2025 was $247.0 million (down 4.26% YoY), and the annual figure for FY2025 was $247.0 million, down 4.26%.
  • Revenue for Q4 2025 was $33.0 million at Arcus Biosciences, up from $26.0 million in the prior quarter.
  • Over the last five years, Revenue for RCUS hit a ceiling of $354.6 million in Q4 2021 and a floor of $9.5 million in Q1 2021.
  • Median Revenue over the past 5 years was $28.5 million (2023), compared with a mean of $55.0 million.
  • Biggest five-year swings in Revenue: surged 3637.93% in 2021 and later tumbled 90.41% in 2022.
  • Arcus Biosciences' Revenue stood at $354.6 million in 2021, then tumbled by 90.41% to $34.0 million in 2022, then crashed by 58.82% to $14.0 million in 2023, then soared by 85.71% to $26.0 million in 2024, then increased by 26.92% to $33.0 million in 2025.
  • The last three reported values for Revenue were $33.0 million (Q4 2025), $26.0 million (Q3 2025), and $160.0 million (Q2 2025) per Business Quant data.